We assess the mechanisms of action, clinical trial outcomes, safety profiles, and practical implementation considerations. Additionally, we evaluate combination and sequential therapy strategies that may enhance patient outcomes.

This article mainly reviews the research progress of currently approved clinical therapeutic drugs for osteoporosis, and updates the new drug strategy for future osteoporosis treatment.

An overview of romosozumab, a therapy for severe osteoporosis with a dual-action mechanism that balances potent bone-building with important safety factors.

Clinical studies on postmenopausal osteoporosis were included, particularly those that included treatment efficacy and drug safety, while studies with missing data were excluded. This study provides clinical references for further application and development of personalized combined and sequential therapies for PMO.

Romosozumab, a new treatment of osteoporosis, is a monoclonal antibody that targets sclerostin and thereby exhibits a dual mechanism of action by stimulating bone formation and inhibiting bone resorption.

Using recently published literature, we aimed to review the effect of using PTH and antiresorptive drugs as a combination therapy for osteoporosis treatment and evaluate the best treatment option.

Subcutaneous teriparatide and abaloparatide should be reserved for patients with severe osteoporosis in whom an increase in bone mineral density is paramount to sustained risk reduction for osteoporotic fracture, or for patients who cannot take a bisphosphonate or denosumab.

Further studies regarding multiple drug therapy must be performed, and detailed research on the mechanisms of action of the drugs is necessary to better understand the molecular basis of the mechanisms and predict and avoid side effects more efficiently.

As with any osteoporosis medication, the decision to use EVENITY should be based on your individual fracture risk, medical history, and a thorough discussion with your healthcare provider about both the benefits and the risks.

Despite established clinical guidelines, managing osteoporosis in older adults remains challenging due to comorbidities, polypharmacy, and variable guideline adherence.